A Study Assessing Persistence Rate and Predictors of Persistence of TNF-alpha Inhibitors and Interleukin 12/23 Inhibitor in all Psoriasis Patients in the Real-World Settings in Hungary

Trial Profile

A Study Assessing Persistence Rate and Predictors of Persistence of TNF-alpha Inhibitors and Interleukin 12/23 Inhibitor in all Psoriasis Patients in the Real-World Settings in Hungary

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2018

At a glance

  • Drugs Adalimumab (Primary) ; Etanercept (Primary) ; Infliximab (Primary) ; Ustekinumab (Primary)
  • Indications Psoriasis
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top